CGRP migraine drugs comparison
NeurologyCompare CGRP pathway therapies for migraine prevention and acute treatment. These targeted therapies block calcitonin gene-related peptide (CGRP), a key molecule in migraine. Options include monthly injections, quarterly infusions, and oral medications.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Aimovig | Amgen/Novartis | SC injection | Monthly | First FDA-approved CGRP antibody; CGRP receptor blocker |
| Ajovy | Teva | SC injection | Monthly or quarterly | Quarterly dosing option; CGRP ligand blocker |
| Emgality | Eli Lilly | SC injection | Monthly | CGRP ligand blocker; also approved for episodic cluster headache |
| Vyepti | Lundbeck | IV infusion | Quarterly | IV CGRP antibody; quarterly infusion; rapid onset |
| Nurtec ODT | Pfizer/Biohaven | Oral (dissolving tablet) | Every other day (prevention) or as needed (acute) | Dual prevention and acute use; oral gepant; dissolves on tongue |
| Qulipta | AbbVie | Oral (tablet) | Daily | Daily oral gepant for prevention only |
| Ubrelvy | AbbVie | Oral (tablet) | As needed for acute migraine | Oral gepant for acute treatment only; no prevention indication |
| Zavzpret | Pfizer | Nasal spray | As needed for acute migraine | Nasal spray gepant for acute treatment; fast-acting; no oral dosing |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.